Capricor Therapeutics (CAPR) is a San Diego-based clinical-stage biotechnology company developing cell and exosome-based therapies for rare diseases. Its lead asset, deramiocel (CAP-1002), is an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy, a progressive muscle-wasting disease. In Friday's session, the stock traded at $7.83, up 3.98% from the previous completed session's close of $7.53 — a move clearly to the upside. The advance had no single piece of new fundamental data behind it: it reflects positioning ahead of the FDA's November 22 target action date on the deramiocel biologics license application, reinforced by a fresh analyst upgrade.
Everything else in the Capricor story is currently subordinate to one scheduled event. The FDA is reviewing the company's BLA for deramiocel, with a PDUFA target action date of November 22, 2026 — a deadline pushed out three months after the agency classified an August submission as a major amendment. The amended package added 24-month open-label extension data from the Phase 3 HOPE-3 trial, more than 900 robustness re-analyses, and an integrated efficacy summary spanning the HOPE-2 and HOPE-3 studies, showing a 1.29-point benefit on the Performance of the Upper Limb scale at a p-value of 0.0087.
Capricor has also narrowed its ask. Rather than a cardiomyopathy label — the indication that drew a 3-to-9 negative advisory committee vote in July — the company is now seeking an indication covering upper-limb impairment in patients aged nine and older, which is the population and endpoint on which HOPE-3 met its primary goal with a 1.1-point difference and a p-value of 0.029. With the decision days away, buyers are effectively taking a view on the approval coin-flip, and the stock has become a pure event-driven instrument.
Sentiment on the sell side has firmed heading into the ruling. JonesTrading raised its rating to Buy from Hold with a $25 target, citing substantial long-term U.S. peak sales potential and an explicit probability weighting on approval. That follows Buy ratings reiterated earlier in November by several other firms, including Oppenheimer, Cantor Fitzgerald and Piper Sandler, whose targets sit far above the current share price. The dispersion is wide — one house still carries a Hold — which is itself a signal of how binary the outcome is viewed. Upgrades of this type are supportive but not transformative; they shift the odds framing rather than the underlying facts.
Capricor's gain stood out because the broader market was not cooperating. With major indices trading lower on the session, the stock's advance diverged from the tape, confirming that the bid was driven by company-specific regulatory anticipation rather than macro or sector momentum. Options flow pointed the same way: put volume on the name jumped roughly 137% above average as investors bought protection against a disappointing ruling, a classic pattern ahead of a binary biotech catalyst.
The move also reads as a partial rebound. Shares peaked near $11.22 on November 11 and slid to $7.53 by November 19, a decline of roughly 33% over six sessions, so Friday's buying represents stabilization rather than a breakout. Even after the bounce, the stock sits deep below its 52-week high of $40.37 and well above its low of $2.96, a range that captures a year of violent repricing around clinical and regulatory news. Volume has been running in the 4.5–5 million share range on recent sessions against an average near 5.4 million, so participation is unremarkable relative to history.
The scale runs from 0 — no meaningful news and an ordinary move for the stock — to 100, meaning transformative news paired with an extreme, rare price move. Capricor scores 28 out of 100. The verified news is moderate in weight: an analyst upgrade and pre-decision positioning ahead of a scheduled regulatory date, with no new clinical or financial disclosure. The price action was not unusual at all by this stock's standards. The 3.98% gain was smaller than the average absolute daily move of about 5.5% over the past 60 sessions, and 34 of those sessions produced a swing of equal or greater size. A modest catalyst and a routine move for this name combine into a low score.
The obvious near-term variable is the FDA's ruling on deramiocel, expected on or around the target date. Beyond approval or rejection, the scope of the approved label — specifically whether it extends beyond upper-limb function in patients aged nine and older — will determine the size of the addressable population in a U.S. market of roughly 15,000 DMD patients.
If approved, execution becomes the question. Capricor ended the third quarter with about $198.5 million in cash and securities and has said that funds operations for at least the next twelve months, with no product revenue to date and no shares sold under its at-the-market program this year. Its San Diego facility is positioned to supply an initial launch. The unresolved distribution dispute with NS Pharma has moved to arbitration, with a hearing expected in mid-2027, leaving commercial rights unsettled. Investors will also track feedback tied to a Form 483 observation from the July inspection, the potential monetization of a rare pediatric disease priority review voucher, and European and Japanese regulatory engagement. Results for the full year typically land in the first quarter.
Tickeron maintains a curated Trending AI Robots page that distills a much larger library of hundreds of AI trading bots covering thousands of tickers down to only those posting the strongest performance under current market conditions. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the list turns over as market regimes shift. For investors looking to pair active ideas like this one with systematic execution, the Trending AI Robots section is a practical starting point.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day RSI Oscillator for CAPR moved out of overbought territory on November 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 26 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CAPR as a result. In 68 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for CAPR turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 36 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
CAPR moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
CAPR broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CAPR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for CAPR crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +14.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in 232 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.125) is normal, around the industry mean (3.596). P/E Ratio (-3.673) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (7.610) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (443.347).
The Tickeron Profit vs. Risk Rating rating for this company is 89 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Develops innovative products for the treatment of cardiovascular diseases
Industry Biotechnology